RSS-Feed abonnieren
DOI: 10.1055/s-2004-835260
© Georg Thieme Verlag Stuttgart · New York
Erkrankungsmodellierung bei Diabetes mellitus
Disease modelling in diabetes mellitusPublikationsverlauf
eingereicht: 15.3.2004
akzeptiert: 8.7.2004
Publikationsdatum:
14. Oktober 2004 (online)

Zusammenfassung
Erkrankungsmodellierung spielt zunehmend eine bedeutende Rolle in der Planung und Umsetzung von gesundheitspolitischen und medizinischen Entscheidungen in der Diabetologie. Anwendung, Nutzen, mathematische Grundlagen und Qualitätskriterien für gute Erkrankungsmodellierung bei Diabetes mellitus sind für praktisch tätige Ärzte schwer zugänglich. Im Folgenden wird ein umfassender Überblick über die Methoden der Erkrankungsmodellierung gegeben, um Qualitätskriterien für die Erkrankungsmodellierung und Modellierungsstudien bei Diabetes mellitus offen zu legen. Für die hohe Qualität von Erkrankungsmodellierung sind von besonderer Bedeutung: die korrekte Auswahl der Datenquellen, die nach Kriterien der evidenzbasierten Medizin orientierte Bewertung der medizinischen und ökonomischen Daten, sinnvolle Zeithorizonte, realistische Diskontierung und Inflationierung, repräsentative Zielpopulationen und die Auswahl einer zutreffenden Kosten-Nutzen-Perspektiven. Darüber hinaus sind die Validierung und der sinnvolle Gebrauch der Modelle bedeutsam.
Summary
Disease modelling increasingly plays an important role in planning and implementing medical decision making in diabetes care. For general practicians it is difficult to find access to application, benefit, arithmetic background and quality criteria of modelling. This review provides a comprehensive overview about the current methods in disease modelling in order to access quality criteria for disease modelling and modelling studies in diabetes care. The following criteria are essential for good quality in disease modelling: adequate choice of data sources, assessment of medical and economic data according to criteria of evidence-based medicine, reasonable time horizons, realistic use of discounting and inflation rates, representative target populations and a realistic perspective of the cost-benefit analysis. Furthermore, validation of disease models and the adequate use of those instruments are of importance.
Literatur
- 1
Randomised Trial of Cholesterol Lowering in 4444 Patients With Coronary Heart
Disease: the Scandinavian Simvastatin Survival Study (4S).
Lancet.
1994;
344
1383-1389
MissingFormLabel
- 2
Hannover Consensus Group .
German Recommendations for Health Care Economic Evaluation Studies. Revised
Version of the Hannover Consensus.
Med Klin (Munich).
2000;
95
52-55
MissingFormLabel
- 3 NICE Guideline for Technology Appraisals: Guidance for Manufacturers and Sponsors
1 - 6-2001. National Institute for Clinical Excellence NICE Ref.: N0014
MissingFormLabel
- 4 Gesundheitsbericht für Deutschland,. Statistisches Bundesamt ISBN 3 - 8246 - 0657 - 7 2002
MissingFormLabel
- 5 MERGE Method for Evaluating research Guideline Evidence. State Health Publication No.(CEB) 1996: 96-204
MissingFormLabel
- 6 DATA Professional User’s Manual,. Treeage Inc., Boston 2001
MissingFormLabel
- 7
Bagust A, Hopkinson P K, Maier W, Currie C J.
An Economic Model of the Long-Term Health Care Burden of Type II Diabetes.
Diabetologia.
2001;
44
2140-2155
MissingFormLabel
- 8
Bagust A, Hopkinson P K, Maslove L, Currie C J.
The Projected Health Care Burden of Type 2 Diabetes in the UK From 2000 to 2060.
Diabet Med.
2002;
19
(Suppl 4)
1-5
MissingFormLabel
- 9
Brown J B, Palmer A J, Bisgaard P, Chan W, Pedula K, Russell A.
The Mt. Hood Challenge: Cross-Testing Two Diabetes Simulation Models.
Diabetes Res Clin Pract.
2000;
50
S57-S64
(Suppl 3)
MissingFormLabel
- 10
Chalmers T C, Smith H, Blackburn B, Silverman B, Schroeder B, Reitman D, Ambroz A.
A Method for Assessing the Quality of a Randomized Control Trial.
Control Clin Trials.
1981;
2
31-49
MissingFormLabel
- 11
Coyle D, Lee K M, O’Brien B J.
The Role of Models Within Economic Analysis: Focus on Type 2 Diabetes Mellitus.
Pharmacoeconomics.
2002;
20
(Suppl 1)
11-19
MissingFormLabel
- 12
DCCT Research Group .
Effect of Intensive Diabetes Treatement on the Development and Progression of
Long-Term Complications in Adolescents With Insulin-Dependent Diabetes Mellitus.
J Pediatr.
1994;
125
177-188
MissingFormLabel
- 13 Drummond M, Stoddart G, Torrance G W. Methods for the Economic Evaluation of Health Care Programmes. Oxford Medical Publications 1987
MissingFormLabel
- 14
Drummond M F, Jefferson T O.
Guidelines for Authors and Peer Reviewers of Economic Submissions to the BMJ:
The BMJ Economic Evaluation Working Party.
BMJ.
1996;
313
275-283
MissingFormLabel
- 15
Goetghebeur M, Rindress D.
Towards a European Consensus on Conducting and Reporting Health Economic Evaluations.
A Report From the ISPOR Inaugural European Conference.
Value in Health.
1999;
2
281-287
MissingFormLabel
- 16
Gold M R, Muennig P.
Measure-Dependent Variation in Burden of Disease Estimates: Implications for
Policy.
Med Care.
2002;
40
260-266
MissingFormLabel
- 17 Gold M R, Siegel J E, Russell L B, Weinstein M C. Cost-Effectiveness in Health & Medicine. Oxford University Press ISBN: 0 195 108 248 1996
MissingFormLabel
- 18
Gozzoli V, Palmer A J, Brandt A, Weiss C, Piehlmeier W, Landgraf R, Renner R.
Increased Clinical and Economic Advantages Using PROSIT (Proteinuria Screening
and Intervention) in Type 2 Diabetic Patients.
Dtsch Med Wochenschr.
2000;
125
1154-1159
MissingFormLabel
- 19
Guyatt G H, Sackett D L, Sinclair J C, Hayward R, Cook D J, Cook R J.
Users’ Guides to the Medical Literature. IX. A Method for Grading Health Care
Recommendations.
JAMA.
1995;
274
1800-1804
MissingFormLabel
- 20
Jefferson T, Demicheli V, Vale L.
Quality of Systematic Reviews of Economic Evaluations in Health Care.
JAMA.
2002;
287
2809-2812
MissingFormLabel
- 21
Klein R, Klein B E, Moss S E, Cruickshanks K J.
The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-Year
Incidence and Progression of Diabetic Retinopathy and Associated Risk Factors
in Type 1 Diabetes.
Ophthalmology.
1998;
105
1801-1815
MissingFormLabel
- 22
Kothari V, Stevens R J, Adler A I, Stratton I M, Manley S E, Neil H A, Holman R R.
UKPDS 60: Risk of Stroke in Type 2 Diabetes Estimated by the UK Prospective
Diabetes Study Risk Engine.
Stroke.
2002;
33
1776-1781
MissingFormLabel
- 23 Palumbo F, Barnes R, Deverka P, Mullany L, Wertheimer A. Report of the ISPOR taskforce on code of ethics. ISPOR http://www.ispor.org/workpaper/code_ethic.htm 2003
MissingFormLabel
- 24
Sanchez L A.
Evaluating the Quality of Published Pharmacoeconomic Evaluations.
Hosp Pharm.
1995;
30
146-142
MissingFormLabel
- 25 Schöffski O, von Schulenburg J M. Gesundheitsökonomische Evaluationen. 2. Auflage Springer-Verlag ISBN: 3 - 540 - 42 584 - 5 2002
MissingFormLabel
- 26
Setyawan J, Palel V, Nichol M B.
Best Practices: Evaluating Modeling Research at ISPOR Using BMJ and ISPOR Guidelines.
ISPOR Connections.
2003;
9 (5)
6-9
MissingFormLabel
- 27
Siegel J E, Torrance G W, Russell L B, Luce B R, Weinstein M C, Gold M R.
Guidelines for Pharmacoeconomic Studies. Recommendations From the Panel on Cost
Effectiveness in Health and Medicine.
Pharmacoeconomics.
1997;
11
159-168
MissingFormLabel
- 28
Stevens R J, Kothari V, Adler A I, Stratton I M.
The UKPDS Risk Engine: a Model for the Risk of Coronary Heart Disease in Type
II Diabetes (UKPDS 56).
Clin Sci.
2001;
101
671-679
MissingFormLabel
- 29
Stevens R J, Stratton I M, Holman R R.
UKPDS58 - Modeling Glucose Exposure as a Risk Factor for Photocoagulation in
Type 2 Diabetes.
J Diabetes Complications.
2002;
16
371-376
MissingFormLabel
- 30
Turner R C, Millns H, Neil H A, Stratton I M, Manley S E, Matthews D R, Holman R R.
Risk Factors for Coronary Artery Disease in Non-Insulin Dependent Diabetes Mellitus:
United Kingdom Prospective Diabetes Study (UKPDS: 23).
BMJ.
1998;
316
823-828
MissingFormLabel
- 31
Veenstra D L, Ramsey S D, Sullivan S D.
A Guideline for the Use of Pharmacoeconomic Models of Diabetes Treatment in
the US Managed-Care Environment.
Pharmacoeconomics.
2002;
20
(Suppl 1)
21-30
MissingFormLabel
- 32
Waugh N.
Grading of Scientific Evidence - a Discussion Paper from SHPIC.
Health Bull (Edinb).
1999;
57
53-63
MissingFormLabel
- 33
Weinstein M C, O’Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce B R.
Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation.
Value Health.
2003;
6
9-17
MissingFormLabel
- 34
Winkelmayer W C, Weinstein M C, Mittleman M A, Glynn R J, Pliskin J S.
Health Economic Evaluations: the Special Case of End-Stage Renal Disease Treatment.
Med Decis Making.
2002;
22
417-430
MissingFormLabel
- 35 Wörz M, Perleth M, Schöffski O, Schwartz F W. Innovative Medizinprodukte im deutschen Gesundheitswesen. Nomos Verlagsgesellschaft ISBN: 3 - 7890 - 8224 - 4 2002
MissingFormLabel
Dr. med. Wendelin Schramm
Bergstraße 18
82152 Krailling
Telefon: 089/8596554
eMail: wendelin.schramm@eumedes.org